Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a


Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului



Yüklə 4,39 Mb.
səhifə267/381
tarix07.01.2022
ölçüsü4,39 Mb.
#80899
1   ...   263   264   265   266   267   268   269   270   ...   381
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AA01 CICLOSPORINUM CAPS. MOI 100 mg

EQUORAL(R) 100 mg 100 mg IVAX-PHARMACEUTICALS

S.R.O.


L04AA01 CICLOSPORINUM SOL. ORALĂ 100 mg/ml

EQUORAL(R) 100 mg/ml IVAX-PHARMACEUTICALS

S.R.O.

SANDIMMUN NEORAL(R) 100 mg/ml NOVARTIS PHARMA GMBH


L04AA01 CICLOSPORINUM CAPS. MOI 25 mg

CICLORAL(R) HEXAL(R) 25 mg 25 mg HEXAL AG

EQUORAL(R) 25 mg 25 mg IVAX-PHARMACEUTICALS

S.R.O.


SANDIMMUN NEORAL(R) 25 mg NOVARTIS PHARMA GMBH
L04AA01 CICLOSPORINUM CAPS. MOI 50 mg

CICLORAL(R) HEXAL 50 mg 50 mg HEXAL AG

EQUORAL(R) 50 mg 50 mg IVAX-PHARMACEUTICALS

S.R.O.


SANDIMMUN NEORAL(R) 50 mg NOVARTIS PHARMA GMBH

________________________________________________________________________________


______________________________________________________________________________

| 548 |L04AX01| AZATHIOPRINUM* | Protocol: L029N |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg

IMURAN(R) 50 mg THE WELLCOME FOUNDATION

LTD.


________________________________________________________________________________
______________________________________________________________________________

| 549 |V06DDN1| AMINOACIZI INCLUSIV COMBINAŢII CU | Protocol: V004N |

| | | POLIPEPTIDE** | |

|_______|_______|____________________________________________|_________________|


________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

V06DDN1 AMINOACIZI INCLUSIV COMPR. FILM.

COMBINAŢII CU

POLIPEPTIDE

KETOSTERIL(R) FRESENIUS KABI DEUTSCHLAND

GMBH


________________________________________________________________________________
SUBLISTA C1 - G26 GLAUCOM.
______________________________________________________________________________

| 550 |S01EC03| DORZOLAMIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01EC03 DORZOLAMIDUM SOL. OFT. 20 mg/ml

TRUSOPT 20 mg/ml MERCK SHARP & DOHME S.R.L

________________________________________________________________________________


______________________________________________________________________________

| 551 |S01EC04| BRINZOLAMIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01EC04 BRINZOLAMIDUM PICĂTURI OFT. - SUSP. 10 mg/ml

AZOPT 10 mg/ml 10 mg/ml ALCON LABORATORIES LTD.

________________________________________________________________________________


______________________________________________________________________________

| 552 |S01ED01| TIMOLOLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01ED01 TIMOLOLUM PICĂTURI OFT. - SOL 0.25%

TIMO-COMOD(R) 0.25% URSAPHARM ARZNEIMITTEL

GMBH&CO.KG

TIMOLOL 0.25% 0.25% E.I.P.I. CO. MED S.R.L
S01ED01 TIMOLOLUM PICĂTURI OFT. - SOL. 0.5%

TIMO-COMOD(R) 0.5% URSAPHARM ARZNEIMITTEL

GMBH&CO.KG

TIMO-GAL(R) 0.5% TERAPIA SA

TIMOLOL 0.5% 0.5% E.I.P.I.CO. MED S.R.L.
S01ED01 TIMOLOLUM GEL OFT. 1 mg/g

NYOLOL GEL 1 mg/g NOVARTIS PHARMA GMBH


S01ED01 TIMOLOLUM PIC. OFT. - SOL. 2.5 mg/ml

TIMOPTIC 2.5 mg/ml MERCK SHARP & DOHME

ROMANIA S.R.L.
S01ED01 TIMOLOLUM PICĂTURI OFT. - SOL. 2.5 mg/ml

ARUTIMOL 0.25% 2.5 mg/ml CHAUVIN ANKERPHARM GMBH


S01ED01 TIMOLOLUM PIC. OFT. - SOL. 5 mg/ml

TIMOPTIC 5 mg/ml MERCK SHARP & DOHME

ROMANIA S.R.L.
S01ED01 TIMOLOLUM PICĂTURI OFT. - SOL. 5 mg/ml

ARUTIMOL 0.5% 5 mg/ml CHAUVIN ANKERPHARM GMBH


S01ED01 TIMOLOLUM PIC. OFT., SOL. 2.5 mg/ml

TIMOLOL RPH 0.25% 2.5 mg/ml ROMPHARM COMPANY SRL


S01ED01 TIMOLOLUM PIC. OFT. SOL. 2.5 mg/ml

TIMABAK 2,5 mg/ml 2.5 mg/ml LABORATOIRES THEA


S01ED01 TIMOLOLUM PIC. OFT. SOL. 5 mg/ml

TIMABAK 5 mg/ml 5 mg/ml LABORATORIES THEA

TIMOLOL RPH 0.5% 5 mg/ml ROMPHARM COMPANY SRL

________________________________________________________________________________


______________________________________________________________________________

| 553 |S01ED02| BETAXOLOLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01ED02 BETAXOLOLUM PICĂTURI OFT. - SUSP. 0.25%

BETOPTIC-S 0.25% ALCON COUVREUR NV
S01ED02 BETAXOLOLUM PIC. OFT. - SOL. 5 mg/ml

BETAX 5 mg/ml ROMPHARM SRL


S01ED02 BETAXOLOLUM PIC. OFTALMICE. SOL 5 mg/ml

BETOPTIC 5 mg/ml ALCON COUVREUR NV


S01ED02 BETAXOLOLUM PIC. OFT. SOL. 5 mg/ml

BETAXOLOL 5 mg/ml TERAPIA SA

________________________________________________________________________________
______________________________________________________________________________

| 554 |S01ED05| CARTEOLOLUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01ED05 CARTEOLOLUM PICĂTURI OFT. - SOL. 20 mg/ml

CARTEOL 2% 20 mg/ml S.I.F.I. SPA
S01ED05 CARTEOLOLUM PIC. OFTALMICE CU ELIB. 20 mg/ml

PREL


FORTINOL EP 2% 20 mg/ml DR. GERHARD MANN

CHEM-PHARM. FABRIK GMBH


S01ED05 CARTEOLOLUM PICĂTURI OFT. - SOL. 2%

CARTEOL 2% 2% S.I.F.I. SPA

________________________________________________________________________________
______________________________________________________________________________

| 555 |S01ED51| COMBINAŢII (BIMATOPROSTUM + TIMOLOLUM) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01ED51 COMBINAŢII PIC. OFT.. SOL. 300 µg/ml + 5 mg/ml

(BIMATOPROSTUM +

TIMOLOLUM)

GANFORT 300 µg/ml + 5 mg/ml ALLERGAN PHARMACEUTICALS

IRELAND


________________________________________________________________________________
______________________________________________________________________________

| 556 |S01ED51| COMBINAŢII (DORZOLAMIDUM + TIMOLOLUM) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01ED51 COMBINAŢII PIC. OFT. - SOL.

(DORZOLAMIDUM +

TIMOLOLUM)

COSOPT FĂRĂ MERCK SHARP & DOHME

CONCENTRAŢIE

________________________________________________________________________________
______________________________________________________________________________

| 557 |S01ED51| COMBINAŢII (LATANOPROSTUM + TIMOLOLUM) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01ED51 COMBINAŢII SOL. OFT.

(LATANOPROSTUM +

TIMOLOLUM)

XALCOM(R) FĂRĂ PFIZER EUROPE MA EEI

CONCENTRAŢIE

________________________________________________________________________________
______________________________________________________________________________

| 558 |S01EE01| LATANOPROSTUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01EE01 LATANOPROSTUM PICĂTURI OFT. - SOL. 5,00%

XALATAN(R) 0.005% PFIZER EUROPE MA EEIG

________________________________________________________________________________


______________________________________________________________________________

| 559 |S01EE03| BIMATOPROSTUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01EE03 BIMATOPROSTUM PIC. OFT. SOL. 0,3 mg/ml

LUMIGAN 0,3 mg/ml 0.3 mg/ml ALLERGAN PHARMACEUTICALS

IRELAND


________________________________________________________________________________
______________________________________________________________________________

| 561 |S01EE04| TRAVOPROSTUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

S01EE04 TRAVOPROSTUM PICĂTURI OFT. SOL. 40 µg/ml

TRAVATAN 40 µg/ml 40 µg/ml ALCON LABORATORIES LTD.

________________________________________________________________________________


SUBLISTA C1 - G27 PEMFIGUS.
______________________________________________________________________________

| 562 |H02AB02| DEXAMETHASONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB02 DEXAMETHASONUM SOL. INJ. 8 mg

DEXAMETHASONE SODIUM 8 mg E.I.P.I.CO. MED S.R.L

PHOSPHATE


H02AB02 DEXAMETHASONUM SOL. INJ. 8 mg/2 ml

DEXAMED 8 mg/2 ml MEDOCHEMIE LTD.

________________________________________________________________________________
______________________________________________________________________________

| 563 |H02AB04| METHYLPREDNISOLONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB04 METHYLPREDNISOLONUM


H02AB04 METHYLPREDNISOLONUM COMPR.

MEDROL 32 32 mg PFIZER EUROPE MA EEI


H02AB04 METHYLPREDNISOLONUM COMPR.

MEDROL 4 mg 4 mg PFIZER EUROPE MA EEI


H02AB04 METHYLPREDNISOLONUM COMPR.

MEDROL A 16 16 mg PFIZER EUROPE MA EEI


H02AB04 METHYLPREDNISOLONUM LIOF. + SOLV. PT. SOL.

INJ.


SOLU-MEDROL 500 mg/7,8 ml 500 mg/7.8 ml PFIZER EUROPE MA EEI
H02AB04 METHYLPREDNISOLONUM LIOF. ŞI SOLV. PT. SOL.

INJ.


SOLU-MEDROL ACT-O-VIAL 125 mg/2 ml PFIZER EUROPE MA EEI
H02AB04 METHYLPREDNISOLONUM LIOF. ŞI SOLV. PT. SOL.

INJ.


SOLU-MEDROL ACT-O- VIAL 250 mg/4 ml PFIZER EUROPE MA EEI
H02AB04 METHYLPREDNISOLONUM LIOF. ŞI SOLV. PT. SOL.

INJ.


SOLU-MEDROL ACT-O-VIAL 40 mg/1 ml PFIZER EUROPE MA EEI
H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ.

LEMOD SOLU 125 mg 125 mg HEMOFARM S.R.L.


H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ.

LEMOD SOLU 40 mg 40 mg HEMOFARM S.R.L.


H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ.

LEMOD SOLU 20 mg 20 mg HEMOFARM S.R.L.


H02AB04 METHYLPREDNISOLONUM LIOF. PT. SOL. INJ.

LEMOD SOLU 500 mg 500 mg HEMOFARM S.R.L.

________________________________________________________________________________
______________________________________________________________________________

| 564 |H02AB07| PREDNISONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB07 PREDNISONUM COMPR. 5 mg

N-PREDNISON 5 mg MEDUMAN SA

PREDNISON 5 mg 5 mg SINTOFARM SA

PREDNISON ARENA 5 mg 5 mg ARENA GROUP SA

PREDNISON GEDEON RICHTER 5 mg 5 mg GEDEON RICHTER ROMANIA SA

PREDNISON MAGISTRA 5 mg 5 mg MAGISTRA C & C

________________________________________________________________________________


______________________________________________________________________________

| 565 |J04BA02| DAPSONUM (4) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J04BA02 DAPSONUM

________________________________________________________________________________
______________________________________________________________________________

| 566 |L01AA01| CYCLOPHOSPHAMIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L01AA01 CYCLOPHOSPHAMIDUM PULB. PT. SOL. INJ./ 1 g

PERF.

ENDOXAN(R) 1 g 1 g BAXTER ONCOLOGY GMBH


L01AA01 CYCLOPHOSPHAMIDUM PULB. PT. SOL. PERF./ 200 mg

INJ. I.V.

ENDOXAN 200 mg 200 mg ACTAVIS S.R.L.
L01AA01 CYCLOPHOSPHAMIDUM PULB. PT. SOL. INJ./ 500 mg

PERF.


ENDOXAN(R) 500 mg 500 mg BAXTER ONCOLOGY GMBH
L01AA01 CYCLOPHOSPHAMIDUM DRAJ. 50 mg

ENDOXAN(R) 50 mg 50 mg BAXTER ONCOLOGY GMBH

________________________________________________________________________________
______________________________________________________________________________

| 568 |L04AA01| CICLOSPORINUM* | |

|_______|_______|____________________________________________|_________________|
Monitorizarea atentă a pacienţilor este obligatorie.


Yüklə 4,39 Mb.

Dostları ilə paylaş:
1   ...   263   264   265   266   267   268   269   270   ...   381




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©muhaz.org 2024
rəhbərliyinə müraciət

gir | qeydiyyatdan keç
    Ana səhifə


yükləyin